Literature DB >> 2451551

German-Austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/IMVP-16 chemotherapy with randomized adjuvant radiotherapy.

H H Gerhartz1, E Thiel, G Brittinger, B Dörken, M Engelhard, W Engert, W Enne, R Fuchs, C H Hagen-Aukamp, D Huhn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2451551     DOI： 10.1007/bf00320022

Source DB:  PubMed          Journal:  Blut        ISSN： 0006-5242


× No keyword cloud information.
  11 in total

1.  Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions.

Authors:  J O Armitage; D D Weisenburger; M Hutchins; D F Moravec; M Dowling; S Sorensen; J Mailliard; J Okerbloom; P S Johnson; D Howe
Journal:  J Clin Oncol       Date:  1986-02       Impact factor: 44.544

2.  [Comparison of CHOP and COP-BLAM chemotherapy in highly malignant non-Hodgkin's lymphoma].

Authors:  H H Gerhartz; E Thiel; E Hiller; C Nerl; W Wilmanns; D Huhn
Journal:  Dtsch Med Wochenschr       Date:  1986-10-03       Impact factor: 0.628

3.  Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphoma.

Authors:  R Willemze; W G Peters; M B van Hennik; W E Fibbe; A M Kootte; M van Berkel; R Lie; C J Rodenburg; J J Veltkamp
Journal:  Scand J Haematol       Date:  1985-01

4.  MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.

Authors:  P Klimo; J M Connors
Journal:  Ann Intern Med       Date:  1985-05       Impact factor: 25.391

5.  Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.

Authors:  E M McKelvey; J A Gottlieb; H E Wilson; A Haut; R W Talley; R Stephens; M Lane; J F Gamble; S E Jones; P N Grozea; J Gutterman; C Coltman; T E Moon
Journal:  Cancer       Date:  1976-10       Impact factor: 6.860

6.  Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.

Authors:  R I Fisher; V T DeVita; S M Hubbard; D L Longo; R Wesley; B A Chabner; R C Young
Journal:  Ann Intern Med       Date:  1983-03       Impact factor: 25.391

7.  Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen.

Authors:  J Laurence; M Coleman; S L Allen; R T Silver; M Pasmantier
Journal:  Ann Intern Med       Date:  1982-08       Impact factor: 25.391

8.  IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy.

Authors:  F Cabanillas; F B Hagemeister; G P Bodey; E J Freireich
Journal:  Blood       Date:  1982-09       Impact factor: 22.113

9.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

Authors:  J H Goldie; A J Coldman
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

10.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome.

Authors:  J E Groopman; R T Mitsuyasu; M J DeLeo; D H Oette; D W Golde
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245
View more
  2 in total

1.  MACOP-B chemotherapy for the treatment of high grade and intermediate grade non Hodgkin's lymphoma.

Authors:  W Oster; T Forsthuber; H H Hennekeuser; H Gamm; A Lindemann; G Schmitz; H G Fuhr; R Hinterberger; H Kreiter; W Thoenes
Journal:  Blut       Date:  1990-01

2.  Long-term follow-up of CHOP-treated non-Hodgkin lymphoma of high-grade malignancy.

Authors:  R Heinz
Journal:  Blut       Date:  1990-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.